At the conclusion of the inspection, the FDA issued a Form 483, outlining eight observations across the facility's units. The ...

Insulin Biosimilar MarketThe global insulin biosimilar market is on track for significant expansion, with an estimated valuation of approximately USD 3,008.0 million in 2024. Exhibiting a year-on-year ...

Mylan President Rajiv Malik commented, "We are pleased with CHMP's decision to recommend approval of Mylan and Biocon's biosimilar insulin glargine. With approximately 60 million people living ...

Biocon, Dr Reddy’s and Mankind Pharma stress on development and manufacturing of biological drugs, look to cash in on a ...

In a separate development, the USFDA also conducted a current Good Manufacturing Practice (cGMP) inspection of Biocon Biologics' insulin manufacturing facility in Malaysia between September 17 and ...

They function as physiological hormones that regulate glucose through GLP-1 receptors, enhancing insulin secretion and suppressing glucagon production. The hormones also slow gastric emptying and ...